Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry
You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes a...
2 Maalis 31min
Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith
Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with ...
23 Helmi 35min
Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug
Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest...
16 Helmi 44min
Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu
Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the A...
9 Helmi 33min
Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte
This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investig...
2 Helmi 39min
Episode 439: Preventing MS with Dr. Bruce Bebo
The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Offi...
26 Tammi 32min
Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi
One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they iden...
19 Tammi 29min
Episode 437: Remembering David Mitchell
I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medicati...
12 Tammi 29min
